fbpx Packaging Design QuickFire Challenge: Unit Dose Technologies - Challenge | JLABS
Header Image

Packaging Design QuickFire Challenge: Unit Dose Technologies

23 days remaining

Up to $100,000 in grant funding

Medical Devices
Consumer Health
Digital Health

As the science and innovation behind products evolve, so must the packaging of those products. Advancing additional options for unit dose packaging may represent the next generation of medication storage.

In the US, the wider adoption of non-reclosable unit dose packaging has been limited due to concern for user-friendly access and design [1], non-recyclable packaging waste, manufacturability and speed at which packaging lines can operate [2].

In addition to helping to prevent accidental unsupervised ingestions (AUIs) of medications by children, some unit dose packaging configurations have also shown to increase medication adherence [3], improve monitoring [4], and reduce risk of contamination [5]. While strides have been made in packaging safety [6], AUIs, when young children self-ingest medicines which are not appropriately kept high and out of sight and reach, can lead to overdose and preventable injury [7].

To inspire innovators to bring potentially groundbreaking unit dose packaging options to the market – with a focus on child-resistant, user-friendly, non-reclosable designs - Johnson & Johnson Innovation together with the packaging innovation team within Johnson & Johnson Consumer Inc. is launching the Packaging Design QuickFire Challenge: Unit Dose Technologies. Potential innovations can include both solids (tablets, capsules and powders) and liquids (solutions and suspensions) in unit-dose formats (e.g. blisters, sachets and stick packs). Primary and secondary packaging or combination of the two are in scope of the challenge.

The innovator(s) with the best idea, potential technology, or potential solution will receive grant funding from a total pool of up to $100,000, access to the global Johnson & Johnson Innovation – JLABS network and mentorship from experts across the Johnson & Johnson Family of Companies.

Rewards

Grant funding from a total pool of up to $100,000
  • Access to the global Johnson & Johnson Innovation - JLABS network
  • Mentorship from experts across the Johnson & Johnson Family of Companies

* Subject to the execution of the necessary documentation and (award) agreements

Application Process

Submissions are expected to focus on the “main criteria” shown below. The “criteria to also consider” will help you differentiate your submission from the rest and the applicant is expected to elaborate on how these criteria can be or not be addressed.

Main criteria:

  • Child Resistant and User Friendly packaging that covers the range of F1 through the F9 **
  • Aim for unit-dose non-reclosable formats.
  • Provides great user experience. Some examples of this are: ease of use/opening, frustration-free opening, portability, attractiveness.
  • Novelty of the idea.

Criteria to also consider:

  • Increased sustainability.
  • Easily integrates into existing packaging lines with minimal modification
  • Support to patience adherence.
  • Cost-effective, scalable & manufacturable
  • Tamper evidence.
  • Barrier needs of pharmaceuticals.
  • Safety of opening and ingestion. (e.g. user cutting due to sharp edges of packaging)

** Ideas are not expected to have a test certificate but should consider as a reference to the 16 CFR § 1700.20.  In general, a child resistant and user friendly test consists of two parts. For the first part, a child must not access to “F” amount of unit doses in a period of 10 minutes. F1 means test failure when a child accesses to 1 unit dose. F9 means failure when a child accesses to 9 unit doses. The second part of the test is the user friendly test. A user should be able to open the packaging in a period of 1 minute.

 

Why this challenge matters to us 

At Johnson & Johnson Innovation, we believe a good idea can come from anywhere, and it’s our goal to find innovative health solutions that aim to improve health around the world. We know that despite parents’ and caregivers’ best efforts at preventing accidental unsupervised ingestions they occur. Working together, we can spark the next great idea that can potentially change the trajectory of health for adults and children around the world.

FAQ

What if I’m having trouble accessing the portal/website?

Make sure your browser is up to date and accepting cookies. You can contact customer service at [email protected] if you are having technical difficulties as well.

Can I submit supporting documents (for example a video) as part of my application?

You will have the opportunity and are encouraged to upload supporting materials such as slide decks, research papers, and videos as part of your application. You may submit a video along with your typed responses. Maximum length is 2 minutes.

Is it ok if some of the information I submit is confidential?

Do not submit confidential information. Only non-confidential information should be submitted and anything you submit will be treated as non-confidential.

What happens with IP (Intellectual Property)?

As this is a no strings attached arrangement, JLABS does not acquire any IP. Any IP creation and/or protection remains the sole responsibility of the inventors.

 Is a patent required to apply?

No, a patent is not required to apply.  However, you should not submit any information that you wish to keep confidential or that may negatively impact upon the future patentability of your invention.

What kind of science / technology is appropriate for the Challenges?

We encourage all to apply. Find out more about what areas we desire to explore here: https://www.jnjinnovation.com/partnering

Who is eligible to apply?

Each Challenge has its own terms & conditions that can be found prior to filling out the application.

What are the specific criteria for application?

 

Submissions are expected to focus on the “main criteria” shown below. The “criteria to also consider” will help you differentiate your submission from the rest and the applicant is expected to elaborate on how these criteria can be or not be addressed.

Main criteria:

  • Child Resistant and User Friendly packaging that covers the range of F1 through the F9 *
  • Aim for unit-dose non-reclosable formats.
    Provides great user experience. Some examples of this are: ease of use/opening, frustration-free opening, portability, attractiveness.
  • Novelty of the idea.

Criteria to also consider:

  • Increased sustainability.**
  • Easily integrates into existing packaging lines with minimal modification
  • Support to patience adherence.
  • Cost-effective, scalable & manufacturable
  • Tamper evidence.
  • Barrier needs of pharmaceuticals.
  • Safety of opening and ingestion. (e.g. user cutting due to sharp edges of packaging)

* Ideas are not expected to have a test certificate but should consider as a reference to the 16 CFR § 1700.20.  In general, a child resistant and user friendly test consists of two parts. For the first part, a child must not access to “F” amount of unit doses in a period of 10 minutes. F1 means test failure when a child accesses to 1 unit dose. F9 means failure when a child accesses to 9 unit doses. The second part of the test is the user friendly test. A user should be able to open the packaging in a period of 1 minute.

Who can I contact if I have questions about the Challenge or the application process?

Please contact [email protected] with any questions.

Where do I apply? And do I have to complete the application in one sitting?

Go to https://jnjquickfire.secure-platform.com to learn more. From there you will be directed to set up an account.

How long should application responses be?  

While there are no specific word count requirements, we recommend that applicants answer each question thoroughly but succinctly, ensuring consideration of any prompts provided within the application.

Applicants also have the ability to upload a non-confidential executive summary and the option to add a non-confidential  supporting slide deck, and/or brief video to your application. While these are not required, we recommend adding any non-confidential available materials that aid in communicating a potential solution including pictures, graphs, etc..

How long is the award period?  

The award period is one year 

Apply Now

Submit your idea today! 


Don’t miss the deadline

Timeline

July 28, 2021
Applications open
October 15, 2021
Submission deadline
December 2021
Finalist & Awardees Selected
Q1 2022
Award Announcement

About Johnson & Johnson Innovation

Johnson & Johnson Innovation LLC works across the pharmaceutical, medical device and consumer health sectors to accelerate early-stage, transformational solutions by catalyzing the best ideas, wherever they are in the world. We do this by harnessing our deep scientific capabilities coupled with a wide range of tools, including customized deal structures, company creation, incubation and startup services, capital investments and other innovative business models that aim to meet the diverse needs of entrepreneurs, scientists and emerging companies. Our goal is to help life science and health technology innovations thrive through collaboration and partnership with the global ecosystem, so that together we can change the trajectory of human health. Meet our passionate team of science and technology experts and learn how to collaborate with us at www.jnjinnovation.com.

About Johnson & Johnson Consumer Inc.

At Johnson & Johnson Consumer Health, we are driven to improve the personal health of people everywhere. Our differentiated portfolio of iconic brands, including Tylenol®, Zarbee's®, Neutrogena®, Aveeno®, Listerine®, OGX®, and Johnson's®, delivers life-enhancing, first-to-market innovation. By combining the power of science with meaningful human insights and digital-first thinking, we help more than 1.2 billion people live healthier lives every day, from their very first day.

 

[1] Schneider PJ. The Impact of Technology on Safe Medicines Use and Pharmacy Practice in the US. Front Pharmacol. 2018;9:1361. Published 2018 Nov 20. doi:10.3389/fphar.2018.01361

[4] Pharmaceutical Commerce, " Pandemic’s drug-administration risks spotlight benefits of unit dose packaging. ” Michael Christel, January 2021.

[5] Packaging of pharmaceuticals: still too many dangers but several encouraging initiatives. Prescrire Int. 2007 Jun;16(89):126-8. PMID: 17585428.

[6] Safe Kids Worldwide, 5 Things to Know about Kids and Medicine, March 2020.

[7] Problems experienced by older people when opening medicine packaging, The International journal of pharmacy practice, September 2013. Ghilbert, Notenboom, Bouvy, Geffen. https://www.researchgate.net/publication/256500034_Problems_experienced_by_older_people_when_opening_medicine_packaging